Loading…

Depression in Parkinson's disease : biogenic amines in CSF of de novo patients

Etiology of depression in Parkinson's disease (PD) is associated with serotonergic dysfunction. Previous studies, supporting this hypothesis, were performed on patients treated with antiparkinsonian drugs. To eliminate the influence of parkinsonian drug therapy and to elucidate significance of...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Neural Transmission 1996-01, Vol.103 (12), p.1441-1445
Main Authors: KUHN, W, MÜLLER, T, GERLACH, M, SOFIC, E, FUCHS, G, HEYE, N, PRAUTSCH, R, PRZUNTEK, H
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c414t-da5614e569c6dda8139b374ebab1d56058a574e4bd4a1e206a2567e45aab6e593
cites cdi_FETCH-LOGICAL-c414t-da5614e569c6dda8139b374ebab1d56058a574e4bd4a1e206a2567e45aab6e593
container_end_page 1445
container_issue 12
container_start_page 1441
container_title Journal of Neural Transmission
container_volume 103
creator KUHN, W
MÜLLER, T
GERLACH, M
SOFIC, E
FUCHS, G
HEYE, N
PRAUTSCH, R
PRZUNTEK, H
description Etiology of depression in Parkinson's disease (PD) is associated with serotonergic dysfunction. Previous studies, supporting this hypothesis, were performed on patients treated with antiparkinsonian drugs. To eliminate the influence of parkinsonian drug therapy and to elucidate significance of different biochemical pathways in PD associated with depression we determined levels of biogenic amines in cerebrospinal fluid (CSF) of 26 untreated "de novo" Parkinsonian patients. Patients were scored with the Hamilton depression scale (HD) and subdivided into groups with HD score > or = 18 and HD score < 18. Diagnosis of depression was made according to DSM III R. Both groups were matched for age and motor disability. In both groups no significant differences appeared between CSF levels of dopamine, noradrenaline, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 3-methoxy-4-hydroxyphenylglycol and 5-hydroxyindole acetic acid, determined by high-performance liquid chromatography. In contrast to previous studies on treated Parkinsonian patients no sign of altered serotonin metabolism especially in context with severity of depression in early stages of PD was found. Due to our results, we suggest, that biochemical markers of depression in CSF of PD may be influenced by antiparkinsonian therapy and that depression in PD may respond to serotonin reuptake inhibitors mainly in later stages of PD.
doi_str_mv 10.1007/BF01271258
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_78685810</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16411557</sourcerecordid><originalsourceid>FETCH-LOGICAL-c414t-da5614e569c6dda8139b374ebab1d56058a574e4bd4a1e206a2567e45aab6e593</originalsourceid><addsrcrecordid>eNqFkc1Lw0AQxRdRav24eBf2IApCdCfZ3Wy8abUqiArqOUySqay2uzXTCv73prTUo6dheD_eg_eEOAB1Bkrl51dDBWkOqXEbog86Mwlom22KvsqUSgpj9bbYYf5QSgHkrid6hUoLDdAXj9c0bYnZxyB9kM_YfvrAMZywbDwTMskLWfn4TsHXEic-EC_AwctQxpFsSIb4HeUUZ57CjPfE1gjHTPuruyvehjevg7vk4en2fnD5kNQa9Cxp0FjQZGxR26ZBB1lRZbmmCitojFXGoeleXTUagVJlMTU2J20QK0umyHbF8dJ32savOfGsnHiuaTzGQHHOZe6sMw7UvyDYrgZj8v_BLjUvikX06RKs28jc0qictn6C7U8JqlzMUf7N0cGHK9d5NaFmja767_SjlY5c43jUYqg9r7HUpFY7l_0Cpx2PPw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15937999</pqid></control><display><type>article</type><title>Depression in Parkinson's disease : biogenic amines in CSF of de novo patients</title><source>Springer LINK Archives</source><creator>KUHN, W ; MÜLLER, T ; GERLACH, M ; SOFIC, E ; FUCHS, G ; HEYE, N ; PRAUTSCH, R ; PRZUNTEK, H</creator><creatorcontrib>KUHN, W ; MÜLLER, T ; GERLACH, M ; SOFIC, E ; FUCHS, G ; HEYE, N ; PRAUTSCH, R ; PRZUNTEK, H</creatorcontrib><description>Etiology of depression in Parkinson's disease (PD) is associated with serotonergic dysfunction. Previous studies, supporting this hypothesis, were performed on patients treated with antiparkinsonian drugs. To eliminate the influence of parkinsonian drug therapy and to elucidate significance of different biochemical pathways in PD associated with depression we determined levels of biogenic amines in cerebrospinal fluid (CSF) of 26 untreated "de novo" Parkinsonian patients. Patients were scored with the Hamilton depression scale (HD) and subdivided into groups with HD score &gt; or = 18 and HD score &lt; 18. Diagnosis of depression was made according to DSM III R. Both groups were matched for age and motor disability. In both groups no significant differences appeared between CSF levels of dopamine, noradrenaline, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 3-methoxy-4-hydroxyphenylglycol and 5-hydroxyindole acetic acid, determined by high-performance liquid chromatography. In contrast to previous studies on treated Parkinsonian patients no sign of altered serotonin metabolism especially in context with severity of depression in early stages of PD was found. Due to our results, we suggest, that biochemical markers of depression in CSF of PD may be influenced by antiparkinsonian therapy and that depression in PD may respond to serotonin reuptake inhibitors mainly in later stages of PD.</description><identifier>ISSN: 0300-9564</identifier><identifier>EISSN: 1435-1463</identifier><identifier>DOI: 10.1007/BF01271258</identifier><identifier>PMID: 9029411</identifier><identifier>CODEN: JNTMAH</identifier><language>eng</language><publisher>Wien: Springer</publisher><subject>Aged ; Biological and medical sciences ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Depression - cerebrospinal fluid ; Depression - etiology ; Dopamine - cerebrospinal fluid ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Neurology ; Norepinephrine - cerebrospinal fluid ; Parkinson Disease - cerebrospinal fluid ; Parkinson Disease - psychology ; Serotonin - cerebrospinal fluid</subject><ispartof>Journal of Neural Transmission, 1996-01, Vol.103 (12), p.1441-1445</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c414t-da5614e569c6dda8139b374ebab1d56058a574e4bd4a1e206a2567e45aab6e593</citedby><cites>FETCH-LOGICAL-c414t-da5614e569c6dda8139b374ebab1d56058a574e4bd4a1e206a2567e45aab6e593</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2526488$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9029411$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>KUHN, W</creatorcontrib><creatorcontrib>MÜLLER, T</creatorcontrib><creatorcontrib>GERLACH, M</creatorcontrib><creatorcontrib>SOFIC, E</creatorcontrib><creatorcontrib>FUCHS, G</creatorcontrib><creatorcontrib>HEYE, N</creatorcontrib><creatorcontrib>PRAUTSCH, R</creatorcontrib><creatorcontrib>PRZUNTEK, H</creatorcontrib><title>Depression in Parkinson's disease : biogenic amines in CSF of de novo patients</title><title>Journal of Neural Transmission</title><addtitle>J Neural Transm (Vienna)</addtitle><description>Etiology of depression in Parkinson's disease (PD) is associated with serotonergic dysfunction. Previous studies, supporting this hypothesis, were performed on patients treated with antiparkinsonian drugs. To eliminate the influence of parkinsonian drug therapy and to elucidate significance of different biochemical pathways in PD associated with depression we determined levels of biogenic amines in cerebrospinal fluid (CSF) of 26 untreated "de novo" Parkinsonian patients. Patients were scored with the Hamilton depression scale (HD) and subdivided into groups with HD score &gt; or = 18 and HD score &lt; 18. Diagnosis of depression was made according to DSM III R. Both groups were matched for age and motor disability. In both groups no significant differences appeared between CSF levels of dopamine, noradrenaline, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 3-methoxy-4-hydroxyphenylglycol and 5-hydroxyindole acetic acid, determined by high-performance liquid chromatography. In contrast to previous studies on treated Parkinsonian patients no sign of altered serotonin metabolism especially in context with severity of depression in early stages of PD was found. Due to our results, we suggest, that biochemical markers of depression in CSF of PD may be influenced by antiparkinsonian therapy and that depression in PD may respond to serotonin reuptake inhibitors mainly in later stages of PD.</description><subject>Aged</subject><subject>Biological and medical sciences</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Depression - cerebrospinal fluid</subject><subject>Depression - etiology</subject><subject>Dopamine - cerebrospinal fluid</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Neurology</subject><subject>Norepinephrine - cerebrospinal fluid</subject><subject>Parkinson Disease - cerebrospinal fluid</subject><subject>Parkinson Disease - psychology</subject><subject>Serotonin - cerebrospinal fluid</subject><issn>0300-9564</issn><issn>1435-1463</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNqFkc1Lw0AQxRdRav24eBf2IApCdCfZ3Wy8abUqiArqOUySqay2uzXTCv73prTUo6dheD_eg_eEOAB1Bkrl51dDBWkOqXEbog86Mwlom22KvsqUSgpj9bbYYf5QSgHkrid6hUoLDdAXj9c0bYnZxyB9kM_YfvrAMZywbDwTMskLWfn4TsHXEic-EC_AwctQxpFsSIb4HeUUZ57CjPfE1gjHTPuruyvehjevg7vk4en2fnD5kNQa9Cxp0FjQZGxR26ZBB1lRZbmmCitojFXGoeleXTUagVJlMTU2J20QK0umyHbF8dJ32savOfGsnHiuaTzGQHHOZe6sMw7UvyDYrgZj8v_BLjUvikX06RKs28jc0qictn6C7U8JqlzMUf7N0cGHK9d5NaFmja767_SjlY5c43jUYqg9r7HUpFY7l_0Cpx2PPw</recordid><startdate>19960101</startdate><enddate>19960101</enddate><creator>KUHN, W</creator><creator>MÜLLER, T</creator><creator>GERLACH, M</creator><creator>SOFIC, E</creator><creator>FUCHS, G</creator><creator>HEYE, N</creator><creator>PRAUTSCH, R</creator><creator>PRZUNTEK, H</creator><general>Springer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>19960101</creationdate><title>Depression in Parkinson's disease : biogenic amines in CSF of de novo patients</title><author>KUHN, W ; MÜLLER, T ; GERLACH, M ; SOFIC, E ; FUCHS, G ; HEYE, N ; PRAUTSCH, R ; PRZUNTEK, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c414t-da5614e569c6dda8139b374ebab1d56058a574e4bd4a1e206a2567e45aab6e593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Aged</topic><topic>Biological and medical sciences</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Depression - cerebrospinal fluid</topic><topic>Depression - etiology</topic><topic>Dopamine - cerebrospinal fluid</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Neurology</topic><topic>Norepinephrine - cerebrospinal fluid</topic><topic>Parkinson Disease - cerebrospinal fluid</topic><topic>Parkinson Disease - psychology</topic><topic>Serotonin - cerebrospinal fluid</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>KUHN, W</creatorcontrib><creatorcontrib>MÜLLER, T</creatorcontrib><creatorcontrib>GERLACH, M</creatorcontrib><creatorcontrib>SOFIC, E</creatorcontrib><creatorcontrib>FUCHS, G</creatorcontrib><creatorcontrib>HEYE, N</creatorcontrib><creatorcontrib>PRAUTSCH, R</creatorcontrib><creatorcontrib>PRZUNTEK, H</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Neural Transmission</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>KUHN, W</au><au>MÜLLER, T</au><au>GERLACH, M</au><au>SOFIC, E</au><au>FUCHS, G</au><au>HEYE, N</au><au>PRAUTSCH, R</au><au>PRZUNTEK, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Depression in Parkinson's disease : biogenic amines in CSF of de novo patients</atitle><jtitle>Journal of Neural Transmission</jtitle><addtitle>J Neural Transm (Vienna)</addtitle><date>1996-01-01</date><risdate>1996</risdate><volume>103</volume><issue>12</issue><spage>1441</spage><epage>1445</epage><pages>1441-1445</pages><issn>0300-9564</issn><eissn>1435-1463</eissn><coden>JNTMAH</coden><abstract>Etiology of depression in Parkinson's disease (PD) is associated with serotonergic dysfunction. Previous studies, supporting this hypothesis, were performed on patients treated with antiparkinsonian drugs. To eliminate the influence of parkinsonian drug therapy and to elucidate significance of different biochemical pathways in PD associated with depression we determined levels of biogenic amines in cerebrospinal fluid (CSF) of 26 untreated "de novo" Parkinsonian patients. Patients were scored with the Hamilton depression scale (HD) and subdivided into groups with HD score &gt; or = 18 and HD score &lt; 18. Diagnosis of depression was made according to DSM III R. Both groups were matched for age and motor disability. In both groups no significant differences appeared between CSF levels of dopamine, noradrenaline, 3,4-dihydroxyphenylacetic acid, homovanillic acid, 3-methoxy-4-hydroxyphenylglycol and 5-hydroxyindole acetic acid, determined by high-performance liquid chromatography. In contrast to previous studies on treated Parkinsonian patients no sign of altered serotonin metabolism especially in context with severity of depression in early stages of PD was found. Due to our results, we suggest, that biochemical markers of depression in CSF of PD may be influenced by antiparkinsonian therapy and that depression in PD may respond to serotonin reuptake inhibitors mainly in later stages of PD.</abstract><cop>Wien</cop><cop>New York, NY</cop><pub>Springer</pub><pmid>9029411</pmid><doi>10.1007/BF01271258</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0300-9564
ispartof Journal of Neural Transmission, 1996-01, Vol.103 (12), p.1441-1445
issn 0300-9564
1435-1463
language eng
recordid cdi_proquest_miscellaneous_78685810
source Springer LINK Archives
subjects Aged
Biological and medical sciences
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Depression - cerebrospinal fluid
Depression - etiology
Dopamine - cerebrospinal fluid
Female
Humans
Male
Medical sciences
Middle Aged
Neurology
Norepinephrine - cerebrospinal fluid
Parkinson Disease - cerebrospinal fluid
Parkinson Disease - psychology
Serotonin - cerebrospinal fluid
title Depression in Parkinson's disease : biogenic amines in CSF of de novo patients
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A36%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Depression%20in%20Parkinson's%20disease%20:%20biogenic%20amines%20in%20CSF%20of%20de%20novo%20patients&rft.jtitle=Journal%20of%20Neural%20Transmission&rft.au=KUHN,%20W&rft.date=1996-01-01&rft.volume=103&rft.issue=12&rft.spage=1441&rft.epage=1445&rft.pages=1441-1445&rft.issn=0300-9564&rft.eissn=1435-1463&rft.coden=JNTMAH&rft_id=info:doi/10.1007/BF01271258&rft_dat=%3Cproquest_cross%3E16411557%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c414t-da5614e569c6dda8139b374ebab1d56058a574e4bd4a1e206a2567e45aab6e593%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=15937999&rft_id=info:pmid/9029411&rfr_iscdi=true